First-in-human study of eliapixant (BAY 1817080), a highly selective P2X3 receptor antagonist: Tolerability, safety and pharmacokinetics. Science ShareTwitterFacebookXingLinkedin dysgeusiaP2X3 receptor antagonistspharmacokineticstaste perception You May Also Like Science 25. Mai 2023 CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes Science 25. Mai 2023 Efficacy and safety of the ghrelin-O-acyltransferase inhibitor BI 1356225 in overweight/obesity: Data from two Phase I, randomised, placebo-controlled studies. Science 25. Mai 2023 (Bersacapavir) In Participants With Moderate Hepatic Impairment.
